FOXA3 Polymorphisms Are Associated with Metabolic Parameters in Individuals with Subclinical Atherosclerosis and Healthy Controls—The GEA Mexican Study

Gilberto Vargas-Alarcón 1*, José Manuel Fragoso 1*, Julian Ramírez-Bello 2 and Rosalinda Posadas-Sánchez 2,4*

Abstract: FOXA3 is a transcription factor involved in the macrophage cholesterol efflux and macrophage reverse cholesterol transport reducing the atherosclerotic lesions. Thus, the present study aimed to establish if the FOXA3 polymorphisms are associated with subclinical atherosclerosis (SA) and cardiometabolic parameters. Two FOXA3 polymorphisms (rs10410870 and rs10412574) were determined in 386 individuals with SA and 1070 controls. No association with SA was observed. The rs10410870 polymorphism was associated with a low risk of having total cholesterol >200 mg/dL, non-HDL-cholesterol >160 mg/dL, and a high risk of having LDL pattern B and insulin resistance adipose tissue in individuals with SA, and with a high risk of having interleukin 10 <p/25 and magnesium deficiency in controls. The rs10412574 polymorphism was associated with a low risk of insulin resistance of the adipose tissue and a high risk of aspartate aminotransferase >p/75 in individual with SA, and with a low risk of LDL pattern B and a high risk of a magnesium deficiency in controls. Independent analysis in 846 individuals showed that the rs10410870 polymorphism was associated with a high risk of aortic valve calcification. In summary, FOXA3 polymorphisms were not associated with SA; however, they were associated with cardiometabolic parameters in individuals with and without SA.

Keywords: atherosclerosis; cardiometabolic parameters; forkhead box; polymorphisms; subclinical atherosclerosis

1. Introduction

Coronary artery disease, the final consequence of the atherosclerotic process, is the leading cause of death worldwide [1]. Atherosclerosis includes three main processes, one the oxidative, in which the LDL particles that penetrate the subendothelial space are oxidized by the action of reactive oxygen species; the second the inflammatory process, which begins when the particles of oxidized LDLs are phagocytosed by resident macrophages at the injury site. During this process, many pro-inflammatory cytokines and chemokines are produced, which perpetuates the damage and leads to the formation of foam cells. Finally, these foam cells become covered with fibrin, forming atherosclerosis plaque, which ruptures, generating a thrombus that will occlude the artery [2]. Thus, macrophages have an essential role in the development and progress of atherosclerosis modulating foam cell formation and the inflammatory response. It has been suggested that macrophages’ reverse cholesterol transport is a protective mechanism for atherosclerosis due to this mechanism preventing macrophages from accumulating excessive cholesterol and, in consequence, diminishing the formation of foam cells [3]. Recently, Li et al. reported in an animal model that the overexpression of FOXA3 in the liver increases the macrophage cholesterol efflux, and macrophage reverse cholesterol transport reducing the atherosclerotic lesions [4].
FOXA3 belongs to the forkhead box (FOX) proteins family: proteins that have been shown to transcriptionally control early development, organogenesis, and metabolism in mice [5]. FOXA3 promotes adipocyte differentiation and has been involved in developing insulin resistance and obesity related with age [6,7]. FOXA3 binds to regions of DNA located in the promoters of genes that code for tyrosine aminotransferase, phosphoenolpyruvate carboxykinase, and insulin-like growth factor-binding protein 1 [8–10], which function as insulin and glucocorticoid-response elements. The gene that encodes FOXA3 is located on chromosome 19 and is polymorphic. In 2015, Adler-Wailes et al. studied the possible association of variants in the FOXA3 gene with metabolic parameters in a group of 392 lean and obese children, adolescents, and young adults [11]. They reported an association of the rs28666870 polymorphism with greater total lean body mass, increased BMI, and appendicular lean mass. Since then, no association studies of FOXA3 polymorphisms with atherosclerosis or metabolic parameters have been conducted. Given the role that FOXA3 plays in macrophage cholesterol efflux and its possible association with insulin resistance, obesity, and atherosclerosis, we consider it interesting to carry out studies on the association of polymorphisms of this gene with cardiovascular diseases and metabolic parameters. Thus, the present study aimed to evaluate the association of two FOXA3 polymorphisms with subclinical atherosclerosis (SA) and cardiometabolic parameters in a cohort well-characterized from the clinical, tomographic, and biochemical points of view.

2. Materials and Methods

2.1. Subjects

The study included 1456 healthy, asymptomatic individuals without a family history of premature coronary artery disease (pCAD) belonging to the Genetics of Atherosclerotic Disease (GEA) Mexican cohort. All individuals were recruited from the blood bank donors and written media invitations at social service centers. Tomography of the chest and abdomen was performed in these individuals using a 64-channel multidetector helical computed tomography system (Somatom Cardiac Sensation, 64, Forchheim, Germany). Information about total abdominal fat (TAF), subcutaneous abdominal fat (SAF), visceral abdominal fat (VAF) [12], liver and spleen attenuation [13], coronary artery calcium (CAC), and aortic valve calcification (AVC) was obtained by the tomography. The CAC and AVC were defined using the Agatston method [14]. After the computed tomography, 386 individuals were classified as individuals with SA (those individuals with CAC score >0) and 1070 as healthy controls (individuals with CAC score = 0). Excluded criteria were congenital heart failure, liver, renal, thyroid, and oncological disease, and premature CAD. Clinical, demographic, biochemical, and anthropometric parameters and cardiovascular risk factors were evaluated as previously described [15–17].

2.2. Genetic Analysis

Two FOXA3 polymorphisms (rs10410870 and rs10412574) were determined using 5’ exonuclease TaqMan assays on an ABI Prism 7900HT Fast Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). To corroborate the adequate assignment of the genotypes in the TaqMan assays, 10% of samples were randomly selected and repeated. These samples were 100% concordant in two independent assays.

2.3. Statistical Analysis

Data are expressed as frequencies, median (interquartile range), or mean ± standard deviation, as appropriate. Either Mann–Whitney U or Student’s t-test was used for continuous variable comparisons, while the Chi-Squared test was employed for categorical variable comparisons. Alleles and genotype frequencies were determined by direct counting. The Chi-Square test determined Hardy–Weinberg’s equilibrium. The association of the polymorphisms with SA and cardiometabolic parameters in SA and healthy controls were evaluated using logistic regression analysis under different inheritance models (additive, codominant 1, codominant 2, dominant, heterozygote, and recessive). The different
models were adjusted for confounding variables as appropriate. Haploview version 4.1 (https://www.broadinstitute.org/haploview/haploview (accessed on 30 March 2022)) (Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA) was used to establish linkage disequilibrium (LD, D′) and construction of haplotypes. The statistical power to detect association of the polymorphisms with SA was determined using the OpenEpi software [http://www.openepi.com/Power/PowerCC.htm (accessed on 30 March 2022)].

2.4. Functional Analysis

The Human-Transcriptome Database for Alternative Splicing (http://h-invitational.jp/, accessed on 20 October 2021), SNP Function Prediction (https://snpinfo.niehs.nih.gov, accessed on 20 October 2021), ESE finder (http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi, accessed on 20 October 2021), Splice Port: An Interactive Splice Site Analysis Tool (http://spliceport.cbcb.umd.edu/SplicingAnalyser.html, accessed on 20 October 2021), SNPs3D (http://www.snp3d.org/, accessed on 20 October 2021) and HSF (http://www.umd.be/HSF/, accessed on 20 October 2021) bioinformatics tools were used to define the possible functional effect of the FOXA3 polymorphisms. These tools showed that both polymorphisms have possible functional effects. The rs10410870 produces a binding site for the CEBP transcription factor, whereas the rs10412574 produces binding sites for HMGIY, HNF4-alpha, SFI, and SRF transcription factors.

3. Results

3.1. Demographic, Clinical, and Biochemical Characteristics

Demographic, clinical, biochemical, and lifestyle characteristics in the studied groups are shown in Table 1. Individuals with SA showed high levels of total cholesterol (p = 0.008), LDL-C (p < 0.001), non-HDL-C (p < 0.001), non-HDL-C > 160 mg/dL (p < 0.001), and low levels of HDL-C (p = 0.015) and magnesium (p = 0.002) when compared to healthy controls. In the same way, the percentage of individuals with total cholesterol >200 mg/dL (p < 0.001), non-HDL-C > 160 mg/dL (p < 0.001), insulin resistance of adipose tissue (p = 0.001), magnesium deficiency (p = 0.04), and aortic valve calcification (p < 0.001) was higher in the individuals with SA than healthy controls.

Table 1. Demographic, clinical, biochemical characteristics, and frequencies of FOXA3 polymorphisms.

|                      | Total Population | Healthy Controls | SA Individuals | p       |
|----------------------|------------------|------------------|----------------|---------|
| n                    | 1456             | 1070             | 386            |         |
| Age (years)          | 53 ± 9           | 51 ± 9           | 59 ± 8         | <0.001  |
| Sex (Male%)          | 41.2             | 75.6             | <0.001         |         |
| Body mass index (kg/m²) | 28.0 (25.6–31.0) | 27.8 (25.4–30.9) | 28.1 (25.9–31.0) | 0.060   |
| Total cholesterol (mg/dL) | 191 (167–214)   | 190 (166–211)    | 198 (169–220)  | 0.008   |
| HDL-cholesterol (mg/dL)       | 118 (97–138)     | 116 (95–134)     | 124 (102–145)  | <0.001  |
| LDL-cholesterol (mg/dL)       | 44 (36–54)       | 45 (36–55)       | 43 (36–50)     | 0.015   |
| Non-HDL-cholesterol (mg/dL)   | 144 (122–168)    | 142 (121–164)    | 153 (128–175)  | <0.001  |
| LDL estimated size       | 1.21 (1.08–1.38) | 1.21 (1.08–1.38) | 1.20 (1.09–1.37) | 0.972   |
| Magnesium concentration (mg/dL) | 2.07 ± 0.17      | 2.08 ± 0.17      | 2.05 ± 0.18    | 0.002   |
| Interleukin-10 concentration (pg/mL) | 0.45 (0.24–1.03) | 0.45 (0.24–1.03) | 0.46 (0.24–1.05) | 0.899   |
| Insulin resistance of adipose tissue | 9.7 (6.2–14.4) | 9.3 (6.1–14.3) | 10.4 (6.7–14.5) | 0.053   |
| Aspartate amino transferase (UI/L) | 25 (21–30)       | 25 (21–30)       | 25 (21–30)     | 0.494   |
| Total cholesterol > 200 mg/dL (%) | 39.6             | 36.7             | 47.7           | <0.001  |
| Non-HDL-cholesterol > 160 mg/dL (%) | 32.1             | 28.5             | 42.0           | <0.001  |
Table 1. Cont.

|                                      | Total Population | Healthy Controls | SA Individuals | p     |
|--------------------------------------|------------------|------------------|----------------|-------|
| LDL pattern B (%)                    | 47.2             | 47.1             | 47.3           | 1.000 |
| Insulin resistance of adipose tissue (%) | 50.4             | 47.9             | 57.7           | 0.001 |
| Elevated aspartate amino transferase (%) | 35.5             | 36.6             | 32.4           | 0.153 |
| Low interleukin-10 concentration (%)  | 31.2             | 31.6             | 30.1           | 0.641 |
| Magnesium deficiency (%)             | 5.9              | 5.2              | 8.2            | 0.040 |
| Current smoking (%)                  | 22.5             | 23.0             | 21.2           | 0.523 |
| Aortic valve calcification (%) *     | 19.5             | 10.8             | 43.5           | <0.001|
| FOXA3 frequency (%)                  |                  |                  |                |       |
| rs10412574                           |                  |                  |                |       |
| CC                                   | 32.1             | 31.9             | 32.6           | 0.858 |
| CT                                   | 47.8             | 47.7             | 48.2           |       |
| TT                                   | 20.1             | 20.5             | 19.2           |       |
| C                                    | 56.0             | 55.7             | 56.7           | 0.884 |
| T                                    | 44.0             | 44.3             | 43.3           |       |
| rs10410870                           |                  |                  |                |       |
| AA                                   | 46.4             | 46.3             | 46.9           | 0.056 |
| AG                                   | 44.5             | 43.6             | 46.9           |       |
| GG                                   | 9.1              | 10.1             | 6.2            |       |
| A                                    | 68.7             | 68.0             | 70.3           | 0.512 |
| G                                    | 31.3             | 32.0             | 29.7           |       |

SA: Subclinical atherosclerosis; LDL: Low density lipoprotein; HDL: High density lipoprotein. * Data available in 846 controls. p values: AS vs. Controls.

3.2. Association of the FOXA3 Polymorphisms with SA, Metabolic Parameters, and Cardiovascular Risk Factors

Genotype frequencies did not deviate from the Hardy–Weinberg equilibrium in any case (HWE, p > 0.05). The statistical power to detect an association with SA considering an unmatched case-control study was 0.80. The FOXA3 polymorphisms were not associated with SA; however, both polymorphisms were associated with some cardiometabolic parameters in SA individuals and healthy controls. In SA individuals, rs10410870 was associated with a low risk of having total cholesterol >200 mg/dL (OR = 0.633 (0.421–0.954) p_heterozygote = 0.029; OR = 0.645 (0.423–0.984) p codominant = 0.042), non-HDL-C > 160 mg/dL (OR = 0.670 (0.473–0.947) p additive = 0.023; OR = 0.571 (0.377–0.865) p dominant = 0.008; OR = 0.584 (0.386–0.885) p heterozygote = 0.011; OR = 0.558 (0.363–0.856) p codominant = 0.008), and a high risk of LDL pattern B (OR = 2.527 (1.044–6.118) p recessive = 0.040) and insulin resistance of adipose tissue (OR = 1.624 (1.055–2.501) p dominant = 0.028; OR = 1.680 (1.090–2.589) p heterozygote = 0.019; OR = 1.705 (1.092–2.664) p codominant = 0.019). On the other hand, rs10412574 was associated with a low risk of the insulin resistance of adipose tissue (OR = 0.522 (0.306–0.890) p recessive = 0.017; OR = 0.538 (0.293–0.987) p codominant = 0.045), and a high risk of having aspartate aminotransferase >p75 (OR = 1.667 (1.033–2.691) p dominant = 0.036; OR = 2.123 (1.145–3.937) p codominant = 0.017). All the models were adjusted for age, sex, and body mass index (Table 2).
Table 2. Association of FOXA3 polymorphisms with metabolic risk factors in SA subject.

| Genotype Frequency | MAF    | Model   | OR [95% CI] | p  |
|--------------------|--------|---------|-------------|----|
| Total cholesterol > 200mg/dL |        |         |             |    |
| rs10410870         | AA     | AG      | GG          |    |
| No (n = 202)       | 0.431  | 0.520   | 0.050       | 0.309 Heterozygote | 0.633 (0.421–0.954) | 0.029 |
| Yes (n = 184)      | 0.511  | 0.413   | 0.076       |       Codominant 1 | 0.645 (0.423–0.984) | 0.042 |
| Non-HDL-C > 160 mg/dL |        |         |             |    |
| rs10410870         | AA     | AG      | GG          |    |
| No (n = 224)       | 0.415  | 0.522   | 0.063       | 0.324 Additive | 0.670 (0.473–0.947) | 0.023 |
| Yes (n = 162)      | 0.543  | 0.395   | 0.062       | 0.259 Dominant | 0.571 (0.377–0.865) | 0.008 |
|                  |        |         |             |  Heterozygote | 0.584 (0.386–0.885) | 0.011 |
|                  |        |         |             | Codominant 1 | 0.558 (0.363–0.856) | 0.008 |
| LDL pattern B      |        |         |             |    |
| rs10410870         | AA     | AG      | GG          |    |
| No (n = 204)       | 0.468  | 0.493   | 0.039       | 0.287 Recessive | 2.527 (1.044–6.118) | 0.040 |
| Yes (n = 182)      | 0.467  | 0.445   | 0.088       | 0.310 Codominant 2 | 0.538 (0.293–0.987) | 0.045 |
| Insulin resistance adipose tissue |        |         |             |    |
| rs10412574         | CC     | CT      | TT          |    |
| No (n = 163)       | 0.318  | 0.433   | 0.248       | 0.463 Recessive | 0.522 (0.306–0.890) | 0.017 |
| Yes (n = 223)      | 0.336  | 0.500   | 0.164       | 0.397 Codominant 2 | 0.538 (0.293–0.987) | 0.045 |
| rs10410870         | AA     | AG      | GG          |    |
| No (n = 163)       | 0.522  | 0.408   | 0.070       | 0.273 Dominant | 1.624 (1.055–2.501) | 0.028 |
| Yes (n = 223)      | 0.430  | 0.514   | 0.056       | 0.300 Heterozygote | 1.680 (1.090–2.589) | 0.019 |
|                  |        |         |             | Codominant 1 | 1.705 (1.092–2.664) | 0.019 |
| Aspartate aminotransferase ≥ p75 |        |         |             |    |
| rs10412574         | CC     | CT      | TT          |    |
| No (n = 261)       | 0.360  | 0.475   | 0.165       | 0.402 Dominant | 1.667 (1.033–2.691) | 0.036 |
| Yes (n = 125)      | 0.256  | 0.496   | 0.248       | 0.496 Codominant 2 | 2.123 (1.145–3.937) | 0.017 |

All the models were adjusted for age, sex, body mass index. HDL-C: High density lipoprotein-cholesterol. MAF: Minor allele frequency.

In healthy controls, rs10410870 was associated with a high risk of having low levels of interleukin 10 (<p25) (OR = 1.612 (1.062–2.447) \( p_{\text{recessive}} = 0.025 \); OR = 1.590 (1.024–2.467) \( p_{\text{codominant2}} = 0.039 \)) and magnesium deficiency (OR = 1.836 (1.053–3.200) \( p_{\text{heterozygote}} = 0.032 \)). On the other hand, rs10412574 was associated with a low risk of LDL pattern B (OR = 0.720 (0.562–0.921) \( p_{\text{heterozygote}} = 0.009 \); OR = 0.751 (0.567–0.996) \( p_{\text{codominant1}} = 0.047 \)), and a high risk of magnesium deficiency (OR = 2.047 (1.153–3.633) \( p_{\text{heterozygote}} = 0.014 \)). All the models were adjusted for age, sex, and body mass index (Table 3).

Table 3. Association of FOXA3 polymorphisms with metabolic risk factors in healthy controls.

| Polymorphism     | Genotype Frequency | MAF    | Model   | OR [95% CI] | p  |
|------------------|--------------------|--------|---------|-------------|----|
| Interleukin 10 < p25 |        |         |         |             |    |
| rs10410870       | AA     | AG      | GG      |    |
| No (n = 732)     | 0.464  | 0.448   | 0.088   | 0.311 Recessive | 1.612 (1.062–2.447) | 0.025 |
| Yes (n = 338)    | 0.444  | 0.422   | 0.134   | 0.399 Codominant 2 | 1.590 (1.024–2.467) | 0.039 |
Table 3. Cont.

| Polymorphism       | Genotype Frequency | MAF     | Model     | OR [95% CI]       | p       |
|--------------------|--------------------|---------|-----------|-------------------|---------|
| LDL pattern B      |                    |         |           |                   |         |
| rs10412574         | CC                 | 0.304   | 0.440     | 0.720 (0.562–0.921) | 0.009   |
| No (n = 566)       | CT                 | 0.512   | 0.183     |                   |         |
| Yes (n = 504)      | TT                 | 0.183   | Heterozygote |                   |         |
| Magnesium deficiency|                   |         |           |                   |         |
| rs10412574         | CC                 | 0.321   | 0.444     | 2.047 (1.153–3.633) | 0.014   |
| No (n = 1014)      | CT                 | 0.468   | 0.210     |                   |         |
| Yes (n = 56)       | TT                 | 0.210   | Heterozygote |                   |         |
| rs10410870         | AA                 | 0.222   | 0.446     |                   |         |
| No (n = 1014)      | AG                 | 0.648   | 0.130     |                   |         |
| Yes (n = 56)       | GG                 | 0.130   | Heterozygote |                   |         |
| AVC (%) *          |                    |         |           |                   |         |
| rs10410870         | AA                 | 0.474   | 0.316     | 1.836 (1.053–3.200) | 0.032   |
| No (n = 755)       | AG                 | 0.422   | 0.104     |                   |         |
| Yes (n = 91)       | GG                 | 0.104   | Heterozygote |                   |         |
| Valvular calcification |                |         |           |                   |         |
| No (n > 755)       | AA                 | 0.462   | 0.098     | 0.318 Additive    | 1.464 (1.052–2.038) | 0.024 |
| Yes = 91           | AG                 | 0.418   | 0.176     | 0.385 Recessive   | 2.315 (1.254–4.276) | 0.007 |
| Codominant 2       | GG                 | 0.385   | 0.176     |                   |         |

All the models were adjusted for age, sex, body mass index. MAF: Minor allele frequency; AVC: Aortic Valve Calcification. * Data were available in 846 control subjects.

3.3. Association of the rs10410870 Polymorphism with AVC

It has been reported that AVC may be present in individuals without CAC. Previously, we established that AVC is present in 8.5% of subjects without CAC [18]. In the present study, we analyzed 846 controls (with CAC = zero), and 91 of them presented with AVC without CAC. Independent analysis in these healthy controls showed that the rs10410870 polymorphism was associated with a high risk of AVC under six models adjusted for several confounding variables. Under the model adjusted by age, sex, BMI, LDL-cholesterol, Type 2 diabetes mellitus, and current smoking, these individuals presented a 2.2-fold higher risk of AVC (OR = 2.239 (1.209–4.147) \( p = 0.010 \)) (Figure 1).

![Figure 1](image-url)

**Figure 1.** Association of the FOXA3 rs10410870 genotype with AVC. Model 1: unadjusted; Model 2: adjusted for age and sex; Model 3: Model 2 + adjusted for body mass index; Model 4: Model 3 + adjusted for LDL-cholesterol; Model 5: Model 4 + adjusted for type 2 diabetes mellitus; Model 6: Model 5 + current smoking.
3.4. Haplotype Analysis

The studied polymorphisms were in high linkage disequilibrium (D’x 100 = 95), and only the TA haplotype was associated with an increased risk of having high levels of aspartate aminotransferase (≥p75) (Table 4).

Table 4. Association of FOXA3 haplotypes with SA and with cardiovascular risk factors in SA and healthy controls.

| Haplotypes | Subclinical Atherosclerosis | OR [95% CI] | p   |
|------------|-----------------------------|-------------|-----|
|            | Yes | No |                 |     |
| H1         | TA  | 0.427 | 0.436 | 0.964 (0.817–1.139) | 0.673 |
| H2         | CG  | 0.291 | 0.312 | 0.905 (0.755–1.083) | 0.278 |
| H3         | CA  | 0.276 | 0.245 | 1.175 (0.976–1.416) | 0.090 |

Coronary Risk Factors

| Subclinical Atherosclerosis |
|-----------------------------|
| Total cholesterol > 200 mg/dL |
| Yes | No | OR [95% CI] | p   |
| H1 | TA  | 0.447 | 0.409 | 1.193 (0.896–1.588) | 0.226 |
| H2 | CG  | 0.279 | 0.303 | 0.895 (0.655–1.221) | 0.485 |
| H3 | CA  | 0.270 | 0.281 | 0.945 (0.689–1.296) | 0.728 |

Cholesterol non-HDL > 160 mg/dL

| Yes | No | OR [95% CI] | p   |
| H1 | TA  | 0.462 | 0.402 | 1.276 (0.956–1.703) | 0.097 |
| H2 | CG  | 0.255 | 0.318 | 0.7391 (0.537–1.016) | 0.063 |
| H3 | CA  | 0.279 | 0.274 | 1.0276 (0.747–1.413) | 0.867 |

LDL pattern B

| Yes | No | OR [95% CI] | p   |
| H1 | TA  | 0.419 | 0.434 | 0.937 (0.703–1.247) | 0.655 |
| H2 | CG  | 0.306 | 0.279 | 1.137 (0.833–1.553) | 0.416 |
| H3 | CA  | 0.271 | 0.280 | 0.956 (0.697–1.313) | 0.785 |

Insulin resistance of adipose tissue

| Yes | No | OR [95% CI] | p   |
| H1 | TA  | 0.405 | 0.464 | 0.780 (0.581–1.075) | 0.098 |
| H2 | CG  | 0.304 | 0.273 | 1.156 (0.837–1.596) | 0.376 |
| H3 | CA  | 0.282 | 0.262 | 1.115 (0.803–1.548) | 0.515 |

Aspartate aminotransferase ≥p75

| Yes | No | OR [95% CI] | p   |
| H1 | TA  | 0.486 | 0.399 | 1.438 (1.062–1.949) | 0.018 |
| H2 | CG  | 0.250 | 0.311 | 0.748 (0.532–1.052) | 0.095 |
| H3 | CA  | 0.254 | 0.287 | 0.835 (0.593–1.177) | 0.304 |

Controls

| Aortic Valve Calcification |
|---------------------------|
| Yes | No | OR [95% CI] | p   |
| H1 | TA  | 0.366 | 0.438 | 0.746 (0.543–1.025) | 0.071 |
Table 4. Cont.

| Haplotypes | Subclinical Atherosclerosis | OR [95% CI] | p |
|-----------|-----------------------------|-------------|---|
| H2        | CG                          | 0.372       | 3.10 | 1.328 [0.964–1.828] | 0.081 |
| H3        | CA                          | 0.249       | 0.244 | 1.019 [0.713–1.456] | 0.916 |

IL-10 < p25

| Haplotypes | Subclinical Atherosclerosis | OR [95% CI] |
|-----------|-----------------------------|-------------|
| H1        | TA                          | 0.414       | 0.445 | 0.833 [0.730–1.064] | 0.198 |
| H2        | CG                          | 0.339       | 0.306 | 1.162 [0.952–1.419] | 0.139 |
| H3        | CA                          | 0.240       | 0.244 | 1.486 [0.845–1.300] | 0.667 |

LDL pattern B

| Haplotypes | Subclinical Atherosclerosis | OR [95% CI] |
|-----------|-----------------------------|-------------|
| H1        | TA                          | 0.444       | 0.430 | 1.060 [0.893–1.258] | 0.504 |
| H2        | CG                          | 0.308       | 0.316 | 0.965 [0.803–1.160] | 0.711 |
| H3        | CA                          | 0.245       | 0.245 | 0.999 [0.819–1.218] | 0.993 |

Magnesium deficiency

| Haplotypes | Subclinical Atherosclerosis | OR [95% CI] |
|-----------|-----------------------------|-------------|
| H1        | TA                          | 0.451       | 0.438 | 1.065 [0.722–1.572] | 0.749 |
| H2        | CG                          | 0.340       | 0.308 | 1.170 [0.777–1.760] | 0.451 |
| H3        | CA                          | 0.206       | 0.247 | 0.777 [0.482–1.257] | 0.306 |

OR: Odds ratio; CI: Confidence intervals.

4. Discussion

FOXA3 is a transcription factor that regulates cholesterol efflux and, in consequence, the atherogenic process. The gene that encodes this factor is polymorphic, and some polymorphisms have been associated with some metabolic parameters [11]. No association studies have been conducted in patients with atherosclerosis. Considering that overexpression of FOXA3 could reduce atherosclerosis, increasing the reverse cholesterol transport [4], we analyzed the distribution of two FOXA3 polymorphisms in individuals with and without SA. Our study provides interesting information on the association of the two FOXA3 polymorphisms with metabolic parameters in two well-defined groups of individuals from a clinical point of view, individuals with AS and healthy subjects. The polymorphisms were not associated with SA; however, rs10410870 was associated with a low risk of having total cholesterol >200 mg/dL and non-HDL-cholesterol >160 mg/dL, and a high risk of having LDL pattern B and insulin resistance of adipose tissue in individuals with SA. This polymorphism was associated with a high risk of having interleukin 10 <p25 and magnesium deficiency in controls. On the other hand, rs10412574 was associated with a low risk of having insulin resistance of adipose tissue and a high risk of having aspartate aminotransferase >p75 in individuals with SA, whereas in controls it was associated with a low risk of having LDL pattern B and a high risk of having a magnesium deficiency. The associations observed in both groups are different, highlighting the association of rs10410870 with a high risk of having insulin resistance adipose tissue in individuals with SA and the association of both polymorphisms with a high risk of magnesium deficiency in the control group. The participation of FOXA3 in adipose tissue has been well established, and it is well-known that the activation of the glucocorticoid receptor upregulates FOXA3 in adipose tissue [7] and promotes adipocyte differentiation through the induction of PPARγ (peroxisome proliferator-activated receptor-gamma) [6]. Ma et al., using Foxa3-null mice fed a high-fat diet, showed that these mice are protected from visceral adipose depot expansion, demonstrating that FOXA3 is an early regulator of adipocyte differentiation [19]. The critical role of the FOXA3 in the cholesterol homeostasis could explain...
the association of rs10410870 with the low risk of having total cholesterol >200 mg/dL and non-HDL-cholesterol >160 mg/dL, and the high risk of having LDL pattern B that was observed in our study. An effect of FOXA3 cannot explain the association of the polymorphisms with a magnesium deficiency; however, it is known that magnesium deficiency produces an increase in LDL levels. In our study, the rs10410870 polymorphism is associated with a high risk of having LDL pattern B, a pattern characterized by a high proportion of LDL particles that are abnormally small and highly atherogenic. On the other hand, magnesium deficiency has been associated with several clinical conditions, including diabetes, hypertension, insulin resistance, and hyperlipidemia [20–23]. In our study, 91 individuals presented with AVC without CAC. In this group, we detected an association of the rs10410870 polymorphism with AVC. Follow-up of these individuals is required to see if they will develop CAC. It is important to consider that the results presented in the study are from the transversal phase of the GEA project. At present, we are finishing the prospective phase of the project. In this phase, we will be able to establish if the individuals with AVC developed CAC or not. It has been proposed that the endothelial dysfunction that produces infiltration of inflammatory cells and lipid deposits in the tissues is the mechanism that initiates AVC [24]. In this context, Li et al. [4] demonstrated that FOXA3 regulates the ApoA-I expression, a molecule that may inhibit monocyte activation and, in consequence, inhibit inflammation [25], a process that could be related to the AVC.

Both studied polymorphisms are located in the promoter region. Bioinformatics analysis showed that rs10410870 produces a binding site for the CEBP transcription factor; in this case, the CEBP binds with more affinity to the A allele when compared to the G allele. CEBP is a family of transcriptional factors involved in the macrophage activation. One of these factors, the CEBP beta, regulates several cytokines such as IL-1B, IL-6, IL-8, IL-12, and TNF alpha, with its consequent role in the inflammatory process [26–29]. The role of this CEBP in inflammation and atherosclerosis was evaluated by Rahman et al. in a mice model. They detected decreased atherosclerotic lesions in C/EBP β−/− mice compared to irradiated ApoE−/− mice when their bone marrow was reconstituted [28]. On the other hand, CEBP is involved in the lipid metabolism in adipose tissue and the liver [30]. On the other hand, the T allele of the rs10412574 polymorphism produces binding sites for HMGIY, HNF4-alpha, SFI, and SRF transcription factors. The HMGIY is a member of the architectural transcription factors of the HGM-1 family with meaningful participation in gene expression and growth regulation [31]. This transcription factor participates in the expression of the chemokine MGSa/GROalpha [32] and endothelial cell adhesion molecule E-selectin [33]. HNF4-alpha is a factor involved in the transcriptional regulation of hepatocyte genes implicated in differentiation, morphogenesis, glucose, and lipid metabolism [34].

Our study has strengths and limitations. Among the strengths, we can highlight having a group of well-characterized individuals from the clinical, demographic, biochemical, and tomography points of view. Our control group only includes those individuals without coronary artery calcium determined by computed tomography (individuals with CAC = zero). Among the limitations, we have the fact that the functional approaches were only defined using bioinformatics tools, and it will be necessary to establish experimental designs that establish the actual functional effect of the polymorphisms included in the study. In addition, we only studied two polymorphisms of the FOXA3 gene; a study that includes more polymorphisms could help define the proper role of this gene in the genetic susceptibility to AS and cardiovascular risk factors.

Considering that the associations described have not been previously reported, studies in other populations will be necessary to establish whether they are unique to the Mexican population or are replicated in other ethnic groups.
5. Conclusions

In summary: our results did not show an association of the FOXA3 polymorphisms with SA; however, the polymorphisms were associated with some cardiometabolic parameters in individuals with and without SA.

Author Contributions: Conceptualization, R.P.-S. and G.V.-A.; methodology, J.M.F. and J.R.-B.; formal analysis, R.P.-S. and J.R.-B.; resources, G.V.-A.; project administration, G.V.-A.; data curation, R.P.-S. and G.V.-A.; writing—original draft preparation, R.P.-S. and G.V.-A.; writing—review and editing, R.P.-S. and G.V.-A. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding. Open Access funding for this article was supported by Instituto Nacional de Cardiología Ignacio Chávez.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics and Research Committees of the Instituto Nacional de Cardiología Ignacio Chávez (protocol 19-1104, 18 February 2019).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available upon request from the corresponding author.

Acknowledgments: We thank the patients and healthy individuals who agreed to participate in the GEA (Genetics of Atherosclerotic Disease) project. We also thank Marva Arellano-Gonzalez and Silvestre Ramírez-Fuentes for their technical assistance and the determination of the polymorphisms included in the study.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. World Health Organization Global Burden of Coronary Heart Disease. Available online: https://www.who.int/health-topics/cardiovascular-diseases/#tab=tab_1 (accessed on 14 March 2022).
2. Kowara, M.; Cudnoch-Jedrzejewska, A. Pathophysiology of Atherosclerotic Plaque Development-Contemporary Experience and New Directions in Research. Int. J. Mol. Sci. 2021, 22, 3513. [CrossRef] [PubMed]
3. Mushenkova, N.V.; Nikiforov, N.G.; Melnichenko, A.A.; Kalmykov, V.; Shakhpazyan, N.K.; Orekhova, V.A.; Orekhov, A.N. Functional Phenotypes of Intraplaque Macrophages and Their Distinct Roles in Atherosclerosis Development and Atheroinflammation. Biomedicines 2022, 10, 452. [CrossRef] [PubMed]
4. Li, Y.; Xu, Y.; Jadhav, K.; Zhu, Y.; Yin, L.; Zhang, Y. Hepatic Forkhead Box Protein A3 Regulates ApoA-I (Apolipoprotein A-I) Expression, Cholesterol Efflux, and Atherogenesis. Arterioscler. Thromb. Vasc. Biol. 2019, 39, 1574–1587. [CrossRef] [PubMed]
5. Friedman, J.R.; Kaestner, K.H. The Foxa family of transcription factors in development and metabolism. Cell. Mol. Life Sci. 2006, 63, 2317–2328. [CrossRef]
6. Xu, L.; Panel, V.; Ma, X.; Du, C.; Hugendubler, L.; Gavriloova, O.; Liu, A.; McLaughlin, T.; Kaestner, K.H.; Mueller, E. The winged helix transcription factor Foxa3 regulates adipocyte differentiation and depot-selective fat tissue expansion. Mol. Cell. Biol. 2013, 33, 3392–3399. [CrossRef]
7. Ma, X.; Xu, L.; Gavriloova, O.; Mueller, E. Role of forkhead box protein A3 in age-associated metabolic decline. Proc. Natl. Acad. Sci. USA 2014, 111, 14289–14294. [CrossRef]
8. Allander, S.V.; Durham, S.K.; Scheimann, A.O.; Wasserman, R.M.; Suwanichkul, A.; Powell, D.R. Hepatic nuclear factor 3 and high mobility group I/Y proteins bind the insulin response element of the insulin-like growth factor-binding protein-1 promoter. Endocrinology 1997, 138, 4291–4300. [CrossRef]
9. Nitsch, D.; Boshart, M.; Schutz, G. Activation of the tyrosine aminotransferase gene is dependent on synergy between liver-specific and hormone-responsive elements. Proc. Natl. Acad. Sci. USA 1993, 90, 5479–5483. [CrossRef]
10. O’Brien, R.M.; Noisin, E.L.; Suwanichkul, A.; Yamasaki, T.; Lucas, P.C.; Wang, J.C.; Powell, D.R.; Granner, D.K. Hepatic nuclear factor 3- and hormone-regulated expression of the phosphoenolpyruvate carboxykinase and insulin-like growth factor-binding protein 1 genes. Mol. Cell. Biol. 1995, 15, 1747–1758. [CrossRef]
11. Adler-Wailes, D.C.; Alberobello, A.T.; Ma, X.; Hugendubler, L.; Stern, E.A.; Mou, Z.; Han, J.C.; Kim, P.W.; Sumner, A.E.; Yanovski, J.A.; et al. Analysis of variants and mutations in the human winged helix FOXA3 gene and associations with metabolic traits. Int. J. Obes. 2015, 39, 888–892. [CrossRef] [PubMed]
12. Kvist, H.; Chowdhury, B.; Grangård, U.; Tylén, U.; Sjöström, L. Total and visceral adipose-tissue volumes derived from measurements with computed tomography in adult men and women: Predictive equations. Am. J. Clin. Nutr. 1988, 48, 1351. [CrossRef] [PubMed]
13. Longo, R.; Ricci, C.; Masutti, F.; Vidimari, R.; Crocè, L.S.; Bercich, L.; Tiritelli, C.; Dalla Palma, L. Fatty infiltration of the liver. Quantification by 1H localized magnetic resonance spectroscopy and comparison with computed tomography. *Investig. Radiol.* 1993, 28, 297–302. [CrossRef] [PubMed]

14. Mautner, G.C.; Mautner, S.L.; Froehlich, J.; Feuerstein, I.M.; Proschan, M.A.; Roberts, W.C.; Doppman, J.L. Coronary artery calcification: Assessment with electron beam CT and histomorphometric correlation. *Radiology* 1994, 192, 619–623. [CrossRef] [PubMed]

15. Posadas-Sánchez, R.; Ocampo-Arcos, W.A.; López-Uribe, A.R.; González-Salazar, M.C.; Cardoso-Saldaña, G.; Mendoza-Pérez, E. Asociación del ácido úrico con factores de riesgo cardiovascular y aterosclerosis subclínica en adultos mexicanos. *Rev. Mex. Endocrinol. Metabol. Nutr.* 2014, 1, 14.

16. Posadas-Sánchez, R.; López-Uribe, A.R.; Posadas-Romero, C.; Pérez-Hernández, N.; Rodríguez-Pérez, J.M.; Ocampo-Arcos, W.A.; Fragoso, J.M.; Cardoso-Saldaña, G.; Vargas-Alarcón, G. Association of the I148M/PNPLA3 (rs738409) polymorphism with premature coronary artery disease, fatty liver, and insulin resistance in type 2 diabetic patients and healthy controls. The GEA study. *Immunobiology* 2017, 222, 960–966. [CrossRef] [PubMed]

17. Medina-Urrutia, A.; Posadas-Romero, C.; Posadas-Sánchez, R.; Jorge-Galarza, E.; Villarreal-Molina, T.; González-Salazar, M.C.; Cardoso-Saldaña, G.; Vargas-Alarcón, G.; Torres-Tamayo, M.; Juárez-Rojas, J.G. Role of adiponectin and free fatty acids on the association between abdominal visceral fat and insulin resistance. *Cardiovasc. Diabetol.* 2015, 14, 20. [CrossRef]

18. Acuña-Valero, J.; Rodas-Diaz, M.A.; Macías-Garrido, E.; Posadas-Sánchez, R.; Juárez-Rojas, J.G.; Medina-Urrutia, A.X.; Cardoso-Saldaña, G.C.; Joge-Galarza, E.; Torres-Tamayo, M.; Vargas-Alarcón, G.; et al. Prevalencia y asociación de la calcificación valvular aórtica con factores de riesgo y aterosclerosis coronaria en población mexicana [Aortic valve calcification prevalence and association with coronary risk factors and atherosclerosis in Mexican population]. *Arch. Cardiol. Mex.* 2017, 87, 108–115.

19. Ma, X.; Xu, L.; Mueller, E. Forkhead box A3 mediates glucocorticoid receptor function in adipose tissue. *Proc. Natl. Acad. Sci. USA* 2016, 113, 3377–3382. [CrossRef] [PubMed]

20. Chutia, H.; Lynnah, K.G. Association of Serum Magnesium Deficiency with Insulin Resistance in Type 2 Diabetes Mellitus. *J. Lab. Physicians.* 2015, 7, 75–78. [CrossRef] [PubMed]

21. Gáman, M.A.; Dobrică, E.C.; Cozma, M.A.; Antonie, N.I.; Stânescu, A.M.A.; Gáman, A.M.; Diaconu, C.C. Crosstalk of Magnesium and Serum Lipids in Dyslipidemia and Associated Disorders: A Systematic Review. *Nutrients* 2021, 13, 1411. [CrossRef]

22. Dominguez, L.; Veronese, N.; Barbagallo, M. Magnesium and Hypertension in Old Age. *Nutrients* 2020, 13, 139. [CrossRef] [PubMed]

23. Piuri, G.; Zocchi, M.; Della Porta, M.; Ficara, V.; Manoni, M.; Zuccotti, G.V.; Pinotti, L.; Maier, J.A.; Cazzola, R. Magnesium in Obesity, Metabolic Syndrome, and Type 2 Diabetes. *Nutrients* 2021, 13, 320. [CrossRef] [PubMed]

24. Tesauro, M.; Mauriello, A.; Rovella, V.; Annicchiarico-Petrizze, M.; Cardillo, C.; Melino, G.; Di Daniele, N. Arterial ageing: From endothelial dysfunction to vascular calcification. *J. Intern. Med.* 2017, 281, 471–482. [CrossRef] [PubMed]

25. Murphy, A.J.; Woolard, K.J.; Hoang, A.; Mukhamedova, N.; Stirzaker, R.A.; McCormick, S.P.; Remaley, A.T.; Sviridov, D.; Chin-Dusting, J. High-density lipoprotein reduces the human monocyte inflammatory response. *Arterioscler. Thromb. Vasc. Biol.* 2008, 28, 2071–2077. [CrossRef] [PubMed]

26. Huber, R.; Pietsch, D.; Panerodt, T.; Brand, K. Regulation of C/EBPβ and resulting functions in cells of the monocytic lineage. *Cell. Signal.* 2012, 24, 1287–1296. [CrossRef] [PubMed]

27. Gorgoni, B.; Maritano, D.; Mathryn, P.; Righi, M.; Poli, V. C/EBP beta gene inactivation causes both impaired and enhanced gene expression and inverse regulation of IL-12 p40 and p35 mRNAs in macrophages. *J. Immunol.* 2002, 168, 4055–4062. [CrossRef] [PubMed]

28. Rahman, S.M.; Jassens, R.C.; Choudhury, M.; Baquer, K.C.; Aikens, R.M.; de la Houssaye, B.A.; Friedman, J.E. CCAAT/enhancer-binding protein β (C/EBPβ) expression regulates dietary-induced inflammation in macrophages and adipose tissue in mice. *J. Biol. Chem.* 2012, 287, 34349–34360. [CrossRef] [PubMed]

29. Thomas, S.R. Haematopoietic-expressed C/EBPβ: A novel transcriptional regulator of hepatic liver metabolism and macrophage foam cells during atherosclerosis? *Atherosclerosis* 2016, 250, 183–185. [CrossRef] [PubMed]

30. Schroeder-Gloeckler, J.M.; Rahman, S.M.; Jassens, R.C.; Qiao, L.; Shao, J.; Roper, M.; Fischer, S.J.; Lowe, E.; Orlicky, D.J.; McManaman, J.L.; et al. CCAAT/enhancer-binding protein beta deletion reduces adiposity, hepatic steatosis, and diabetes in Lepr(db/db) mice. *J. Biol. Chem.* 2007, 282, 15717–15729. [CrossRef] [PubMed]

31. Bustin, M.; Reeves, R. High-mobility-group chromosomal proteins: Architectural components that facilitate chromatin function. *Prog. Nucleic Acids Res.* 1996, 53, 54–100. [CrossRef] [PubMed]

32. Wood, L.D.; Farmer, A.A.; Richmond, A. HMGI(Y) and Sp1 in addition to NF-kappa B regulate transcription of the MGS/ cationic GRO alpha gene. *Nucleic Acids Res.* 1995, 23, 4210–4219. [CrossRef] [PubMed]

33. Whitley, M.Z.; Thanos, D.; Read, M.A.; Maniatis, T.; Collins, T. A striking similarity in the organization of the E-selectin and beta interferon gene promoters. *Mol. Cell. Biol.* 1994, 14, 6464–6475. [PubMed]

34. Babeu, J.P.; Boudreau, F. Hepatocyte nuclear factor 4 intervening liver in involvement and intestinal inflammatory networks. *World J. Gastroenterol.* 2014, 20, 22–30. [CrossRef] [PubMed]